Aeglea BioTherapeutics (NASDAQ:AGLE) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the biotechnology company’s stock.

Several other research firms have also commented on AGLE. Jonestrading restated a “hold” rating on shares of Aeglea BioTherapeutics in a research report on Wednesday, April 12th. Wells Fargo & Company cut Aeglea BioTherapeutics from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, April 12th. Lifesci Capital lowered Aeglea BioTherapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Aeglea BioTherapeutics in a research report on Friday, March 3rd. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $1.88.

Aeglea BioTherapeutics Stock Performance

AGLE opened at $0.15 on Friday. Aeglea BioTherapeutics has a 12-month low of $0.14 and a 12-month high of $1.64. The company has a market cap of $9.55 million, a price-to-earnings ratio of -0.17 and a beta of 1.75. The company’s 50 day moving average is $0.22 and its 200 day moving average is $0.48.

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) last issued its earnings results on Thursday, March 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. Aeglea BioTherapeutics had a negative net margin of 6,678.20% and a negative return on equity of 132.05%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.17 million. As a group, analysts predict that Aeglea BioTherapeutics will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AGLE. Renaissance Technologies LLC lifted its holdings in Aeglea BioTherapeutics by 283.5% during the 2nd quarter. Renaissance Technologies LLC now owns 582,444 shares of the biotechnology company’s stock worth $294,000 after buying an additional 430,576 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Aeglea BioTherapeutics by 52.4% in the 4th quarter. Geode Capital Management LLC now owns 600,455 shares of the biotechnology company’s stock valued at $270,000 after acquiring an additional 206,435 shares in the last quarter. Millennium Management LLC grew its holdings in Aeglea BioTherapeutics by 23.1% during the second quarter. Millennium Management LLC now owns 521,915 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 98,001 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Aeglea BioTherapeutics by 7.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 106,810 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 7,333 shares during the period. Finally, Two Sigma Advisers LP lifted its position in Aeglea BioTherapeutics by 76.9% during the third quarter. Two Sigma Advisers LP now owns 409,900 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 178,200 shares during the last quarter. Hedge funds and other institutional investors own 78.01% of the company’s stock.

About Aeglea BioTherapeutics

(Get Rating)

Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.